This article provides an overview of movement disorders that present in childhood. Key clinical features are discussed, and a brief guide to management strategies is provided. Recent advances in the field of pediatric movement disorders are also a focus of the article. Recent Findings: Advances in genetic technologies and cell biology have contributed greatly to the elucidation of underlying disease mechanisms in childhood movement disorders. This article discusses the expanding spectrum of both genetic and acquired movement disorders that present in childhood, including benign, acquired, genetic, and psychogenic movement disorders. Summary: Movement disorders in childhood comprise a wide spectrum of both genetic and acquired diseases, ranging from benign self-limiting conditions to more progressive phenotypes associated with significant morbidity and mortality. Elucidation of the underlying cause is achieved through accurate history, detailed clinical examination, review of video footage (including home videos), and, where appropriate, neuroimaging and laboratory investigations. Early accurate diagnosis will facilitate the instigation of appropriate management strategies.
INTRODUCTION
Movement disorders in childhood comprise a heterogeneous group of conditions that lead to impairment of voluntary movement, abnormal postures, or inserted involuntary movements. Movement disorders in children are often classified into two main categories: hyperkinetic/dyskinetic movement disorders (including stereotypies, tics, tremor, dystonia, and chorea) 1 and hypokinetic movement disorders, encompassing parkinsonian phenotypes. 2 A number of other systems classify disorders into subgroups according to temporal and spatial patterns, clinical features, motor signs, and underlying etiology (molecular genetic features or neuropathology).
A wide range of movement disorders are described in childhood, from benign self-limiting transient phenomena to more progressive disorders associated with significant morbidity and mortality. Movement disorders in childhood may present acutely, subacutely, or in a more chronic manner. The underlying etiologies for childhood movement disorders are diverse and include both acquired and genetic conditions. Significant advances in genetic technologies have facilitated the discovery of a number of novel disease-causing Supplemental digital content: Videos accompanying this article are cited in the text as Supplemental Digital Content. Videos may be accessed by clicking on links provided in the HTML, PDF, and app versions of this article; the URLs are provided in the print version. Video legends begin on page 1182. genes and movement disorder syndromes in childhood.
Accurate diagnosis of childhoodonset movement disorders requires careful ascertainment of clinical history, detailed neurologic examination (for recognition of phenomenology and associated features), and a broad knowledge of potential differential diagnoses. This article provides an updated overview of movement disorders in childhood, with particular focus on newly recognized conditions.
BENIGN MOVEMENT DISORDERS OF CHILDHOOD
A number of relatively benign movement disorders of childhood have been identified, relating to specific stages of normal development ( Table 7 -1). 3 The underlying basis of such movement disorders is not fully understood, but some are thought to be a manifestation of the developing brain, reflecting central nervous system immaturity. The majority of these conditions occur early in life, during the neonatal period, infancy, and early childhood, with resolution of symptoms over time. Furthermore, other neurologic symptoms are rarely present, and most children are found to have a normal neurologic examination. Accurate recognition is crucial to avoid unnecessary investigations and provide families with reassurance regarding long-term prognosis, where appropriate.
TICS, TOURETTE SYNDROME, AND STEREOTYPIES Tics are the most common movement disorder in childhood and can be separated into motor tics or vocal tics. Motor tics typically involve the face, head, and shoulders, although they can affect any body part. The most common motor tics are blinking, eye movements, grimacing, and head movements. The most common vocal tics are throat clearing and grunts. However, a remarkable breadth of motor and vocal tics may be observed from any body part. Tics are stereotypical and repetitive for periods of time, but tend to change over time (months and years). The characteristic features of tics are their repetitive stereotypical nature, fluctuation (waxing and waning), suppressibility, and suggestibility.
Tic duration is used to separate tics into transient tic disorder, which occurs for less than 12 months, and chronic disorders, which occur for longer than 12 months, and include: chronic motor tic disorder, chronic vocal tic disorder, and when both motor and vocal tics are present, Tourette syndrome. The time of 12 months is used in the definition, as when tics last for longer than 12 months they are more likely to continue for much of childhood and adolescence. Despite being common (transient tics affect approximately 5% to 10% of children at some time, and Tourette syndrome affects 0.5% of children), these disorders remain poorly understood and underrecognized by both clinicians and laypeople. Patients are often referred to opticians (for blinking and eye movements), otolaryngologists (for throat clearing), or respiratory physicians (for repetitive cough) before a diagnosis is made. Tics are often mislabeled as habits.
Neurodevelopmental disorders are also overrepresented in patients with Tourette syndrome, and a significant minority of patients may have autism spectrum disorder, sensory processing disorder, or other dysexecutive problems, which can affect school and general functioning. Tourette syndrome is not a disease but a symptom syndrome, and the etiology is likely multifactorial with genetic vulnerability factors plus environmental factors. 4 
KEY POINTS
h Movement disorders in childhood are heterogeneous and range from mild self-limiting phenotypes to more severe progressive neurodegenerative disorders.
h A number of benign movement disorders of childhood have been identified, which are transient in nature and usually have a good long-term prognosis. The most important management aspect of Tourette syndrome is to make a confident diagnosis and educate the child, family, and school that Tourette syndrome is a neurologic disorder and is not the child's fault so that the family understands and accepts the diagnosis. In addition, informing the family that the tics typically improve between 11 and 20 years of age can be reassuring. In approximately 80% of patients, psychoeducation is all that is required. The need for more intervention is dictated by impairment in social or global functioning. When impairment occurs, treatment can include psychological approaches including tic reversal therapy. When medical treatments are required, the family needs to understand that medication will only reduce tics by 30% to 50% at best, although this can be useful. In general, clonidine or guanfacine is the first-line therapy, and antipsychotics such as risperidone, are restricted to more severe cases. Other agents including tetrabenazine, baclofen, topiramate, and benzodiazepine can be considered, and deep brain stimulation (DBS) can be used for the most severely affected patients who have failed medical therapy and who have failed to improve in adolescence. Screening for comorbid diagnoses of attention deficit disorder, obsessive-compulsive disorder, or associated problems, is essential as these are frequently more important to treat than the tics.
Stereotypy is a common movement phenotype and a normal feature of infant development, but when stereotypy continues beyond this period, the episodes can become concerning to parents (less so for the child) because of the unusual nature of the episodes and the potential for social stigmatization. Stereotypies are repetitive movements; classic examples include rocking, flapping, and bodytensing. However, some stereotypies are extremely complex, including twisting, grimacing, and posturing. The most important characteristics of stereotypy are: (1) the movements have a stereotypical nature (ie, the episodes are similar); (2) the patient is partially distractible (although the child may subsequently need to complete the movement after being distracted); and (3) the episodes are often more likely to occur with certain stimuli, such as excitement or anticipation (eg, waiting in a line), participation in a favorite activity (eg, watching television), or sometimes boredom (eg, riding in the back of a car). Parental videos are highly informative and essential for diagnosis. Stereotypy is more common in children with developmental disorders, such as language delay and autism spectrum disorder, but complex motor stereotypy can also occur in normally developed children. 5 Detailed assessment for subtle neurodevelopmental disorders is important as this may present therapeutic options, although the treatment of stereotypy itself is challenging and drugs are ineffective. Psychological approaches may be useful in wellmotivated cognitively able individuals. Many normally developed older children with stereotypy have associated neuropsychiatric conditions, such as attention deficit hyperactivity disorder, anxiety, or tics. 5 Some children with complex stereotypy describe complex, sometimes imaginary, thoughts during the movements. 6 ACQUIRED MOVEMENT DISORDERS Acquired brain disorders such as traumatic brain injury, hypoxic ischemic injury, and infectious and autoimmune processes can result in transient or persistent movement disorders. 
Cerebral Palsy (Hypoxic Ischemic)
The classic movement disorder cerebral palsy phenotype is dystonic cerebral palsy, although other terms such as dyskinetic cerebral palsy or choreoathetoid cerebral palsy are sometimes used depending on the movement phenomenology. Classic teaching is that dystonic cerebral palsy occurs as a consequence of hypoxic ischemic injury, predominantly to the subcortical structures during early brain development. Although a clear history of brain injury is present in a proportion of cases, no such history exists in a significant proportion, and many patients with dystonic cerebral palsy have a normal MRI. It is increasingly likely that some patients labeled as having dystonic cerebral palsy in fact have a genetic movement disorder or another disease mechanism. A positive family history of neurologic disease; a fluctuating course; apparently normal early development; a normal MRI; and clinical features such as progressive dystonia, exercise-induced dystonia, or oculogyric crises are some features that should alert the clinician to the possibility this is not typical dystonic cerebral palsy.
Infectious Causes
Movement disorders do not commonly result from direct infectious causes of encephalitis but are more typically observed in autoimmune encephalitis. However, a number of infections can affect subcortical structures, resulting in movement disorders. The most important cause worldwide is Japanese B encephalitis, which remains endemic in certain parts of the world, especially Asia, and commonly results in a severe dystonic-akinetic phenotype. 7 Other infections that can affect subcortical structures and result in movement disorders include Epstein-Barr virus, Enterovirus, group A streptococcus, influenza, and Mycoplasma pneumoniae, among others. Whether these encephalitides are due to direct invasion of the central nervous system by the microorganism or are postinfectious or immune mediated is not always clear; both mechanisms appear to be possible and may overlap. One of the most important examples of this overlap between infection and autoimmunity is the postYherpes simplex encephalitis relapse syndrome. In the weeks after presentation with typical herpes simplex encephalitis, 20% of patients will relapse with encephalopathy and movement disorders (typically chorea). During the relapse, the CSF no longer demonstrates positive herpes simplex polymerase chain reaction, but instead the CSF harbors autoantibodies against the N-methyl-D-aspartate (NMDA) receptor. 8, 9 These patients benefit from immunosuppression. This syndrome therefore represents a prototypic example of infectiontriggered autoimmunity. 10 
Postinfectious/Autoimmune Causes
The presence of movement disorders in the context of encephalitis is strongly predictive of an autoimmune encephalitis, particularly antiYNMDA receptor encephalitis. 11 Almost all children with antiYNMDA receptor encephalitis have movement disorders, and young children often have generalized chorea and dystonia that may be impairing, whereas older children and adults are more likely to have more localized movements of the face, such as orobuccal dyskinesia. In children, almost any movement disorder is possible in the course of disease, and the movements typically evolve over the course of disease, with chorea, dystonia, stereotypy, akinesia, and tremor all observed. Arguably the most characteristic movement disorder of antiYNMDA receptor encephalitis is the repetitive stereotypical clonic or tonic posturing that results in purposeless, repetitive, and sometimes violent agitated movements. 12 Some of the postures can be reminiscent of the syndrome catatonia. The movements rarely occur in isolation but instead are part of a complex evolving encephalopathy syndrome with aphasia, psychosis, agitation, and dysautonomia as well as nonspecific encephalitis fea-tures such as seizures and confusion (Case 7-1). The syndrome is now very recognizable, and, if suspected, immunosuppressive therapy should be started while awaiting results of CSF and serum NMDA receptor antibody tests. Early treatment and the willingness to use second-line immunotherapy (rituximab or cyclophosphamide) improve outcomes and reduce relapses. 13 Other autoimmune encephalopathies include basal ganglia encephalitis, which is a rare pure basal ganglia inflammatory encephalitis with restricted Case 7-1 A previously healthy 7-year-old girl presented with a change in behavior and restlessness. Over the following week, the illness progressed, with increasing agitation and apparent delusional thoughts with repeated statements of ''I'm going to die.'' Examination revealed a generalized movement disorder with repetitive restless movements, including scratching her face and cycling movements of her legs. In the second week, she had three focal seizures and became mute. MRI brain was normal, CSF showed 20 monocytes/mm 3 , although infectious screening of CSF and blood was negative including herpes simplex virus, and EEG showed nonspecific slowing. A clinical diagnosis of antiYN-methyl-D-aspartate (NMDA) receptor encephalitis was made, and a 5-day course of IV methylprednisolone was started in addition to IV immunoglobulin (IVIg). Ten days later, she showed no apparent improvement and remained mute and unresponsive to her parents and environment despite apparently being awake. She only slept for 2 hours a night and had ongoing purposeless stereotypical repetitive movements of her limbs and face. Fourteen days after commencing immunotherapy, the CSF NMDA receptor antibodies returned positive, and, given the lack of improvement, rituximab 375 mg/m 2 weekly for 4 weeks was started. Ten days after starting rituximab, she started to make improvements. Her movement disorder evolved to dystonic posturing, but she became more interactive and less agitated. After a 2-month admission, she was discharged on a 6-month total oral prednisolone taper. She remained B-cell depleted for 6 months and continued to improve. At 12 months, all of her symptoms had resolved, although her school performance lagged slightly behind.
Comment. This case exemplifies the movement phenomenology in antiYNMDA receptor encephalitis, with restless stereotypical movements later followed by dystonia. The case also exemplifies the fact that the movement disorder rarely occurs in isolation and is almost always accompanied by other changes in neurologic function, in this case, cognitive changes, loss of speech, seizures, and agitated psychosis. The case also demonstrates that it is possible to make a clinical diagnosis and start treatment before getting confirmatory diagnostic results. A positive antibody result empowers the clinician to use rituximab or other immunosuppression if the patient does not adequately respond to first-line therapy.
inflammation of the basal ganglia, typically presenting in young children with dystonia and akinesia or sometimes chorea, plus change in behavior. 14 Early use of steroids, immunoglobulin, and plasma exchange can improve outcomes and reduce the chance of residual atrophy and gliosis of the basal ganglia. These patients may harbor autoantibodies against dopamine-2 receptor.
Sydenham chorea is still endemic in the world and remains one of the more common causes of acute chorea. Triggered by "-hemolytic streptococci as part of rheumatic fever, Sydenham chorea is a neuropsychiatric syndrome with acute behavioral change in addition to chorea. Although the disease is usually monophasic and selfresolving, a significant proportion of patients are left with minor chorea or residual neuropsychiatric disease. For this reason, it can be argued that patients should be treated with acute immunotherapy as some evidence exists that this can improve short-term outcomes, 15 although long-term data are lacking.
Infection-mediated tics and emotional lability, either as a poststreptococcal phenomenon (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections [PANDAS]) or other postinfectious phenomenon (pediatric acute neuropsychiatric syndrome [PANS]), are uncommon. Although tics are part of PANS, acute anxiety, separation anxiety, and obsessive-compulsive symptoms with repetitive urination are more characteristic features of PANS than PANDAS. 16 Although these entities are clearly infection associated and may benefit from antibiotics or immunomodulation, the evidence that these disorders are definitely autoimmune is lacking at this time.
Progressive encephalopathy with rigidity and myoclonus (PERM) is a rare syndrome considered part of the stiff person syndrome spectrum and is associated with glycine receptor antibodies. 17 More common in adults, this syndrome has been described in young children who present with mild encephalopathy, irritability, rigidity, and stimulus-induced startle, which is distressing. The syndrome is an autoimmune version of genetic hyperekplexia, and, given the immunotherapy responsiveness of PERM, it is important to recognize. Autoantibodies against DPPX, a subunit of potassium channels, can be associated with an autoimmune encephalitis with symptoms of diarrhea, weight loss, encephalopathy, and movement disorders such as myoclonus, rigidity, and startle. 18 Autoantibodies against ,-aminobutyric acid (GABA)-A receptors can sometimes be associated with autoimmune encephalitis and movement disorders, although status epilepticus appears to be the dominant phenotypic association of this autoantibody. 19 Opsoclonus myoclonus ataxia syndrome is a recognizable entity that can be paraneoplastic (neural crest tumors), triggered by infection, or idiopathic. The diagnosis is clinical, and no defining autoantibody is known. Suspicion should result in screening for neural crest tumors and initiation of immunotherapy. Some patients appear to respond quickly to steroids and IV immunoglobulin (IVIg), whereas others require rituximab or more chronic immunosuppression. General principles of treatment include early intervention and induction of complete remission to avoid residual symptoms as they may infer ongoing inflammation and risk of permanent neurocognitive disability. 20 More aggressive intervention appears to have changed the natural history of this condition, with better outcomes now described. 21 
KEY POINTS
h Sydenham chorea continues to be an important cause of immune-mediated chorea worldwide and can be associated with significant long-term morbidity.
h Features of opsoclonus myoclonus ataxia syndrome should prompt screening for neural crest tumors and initiation of immunotherapy.
Although rare, the emergence of such autoimmune encephalopathies has radically changed the clinical approach to the child with acute autoimmune movement disorders. Rather than observation and symptomatic therapy, increasing willingness exists to use immunotherapies, as early recognition and intervention appear to improve outcomes.
Stroke and Other Space-Occupying Lesions
Any patient presenting with an acute movement disorder requires neuroimaging, and MRI is the optimal modality. Movement disorders that affect one side of the body, referred to as hemidystonia or hemichorea, can be caused by acute vascular events, such as stroke or vasculitis, and MRI with diffusion-weighted imaging is part of the diagnostic pathway. Moyamoya disease and other vasculopathies may present with chorea, and surgical intervention can improve the movement disorder and reduce the risk of ongoing stroke. 22 Likewise, tumors or other space-occupying lesions involving the subcortical structures may present with acute or subacute onset of movement disorders, and imaging is diagnostic.
Toxic/Iatrogenic Causes Iatrogenic or toxic mechanisms are important causes of movement disorders, but they are usually moderately straightforward to diagnose as a clear temporal association of drug usage and onset of movement disorder usually exists. Direct questioning regarding potential drug ingestion is therefore an important part of the clinical history in children who acutely present with involuntary movements or postures. More common associations include neuroleptic-induced dystonia/neuroleptic malignant syndrome, antiepileptic drugYinduced dyskinesia in (often genetic) epilepsies, amphetamine or other stimulant use or misuse, withdrawal movement disorders such as with midazolam infusion withdrawal, and cancer drug use resulting in movement disorders, often with leukoencephalopathies. 23 
Treatment Strategies for Acquired Movement Disorders
The primary approach to the child with an acquired movement disorder is defining the etiology and then treating the underlying cause. Defining and treating the cause of disease in a timely fashion provides the best chance of a good outcome and reduces the potential destructive nature of disease. Symptomatic treatment of acquired movement disorders is generally unsatisfactory, and patients with autoimmune movement disorders appear to be vulnerable to drug adverse events; for example, neuroleptic drugs can induce akinesia and neuroleptic malignant syndrome in Sydenham chorea and antiYNMDA receptor encephalitis, respectively. 24 Agents such as benzodiazepines or " 2 -agonists may be safer treatments for acquired movement disorders, but the evidence base is limited.
GENETIC MOVEMENT DISORDERS
Advances in molecular genetic techniques, such as chromosomal microarray studies, targeted next-generation multiple gene panels, and whole exome/genome sequencing strategies, have led to a significant increase in the diagnosis of genetic movement disorders of childhood. Furthermore, a large number of new genetic disorders have been identified and clinically characterized.
Primary Genetic Dystonia
Traditionally, genetic dystonias have been classified according to a DYT number assigned to each disease locus. Paroxysmal disorders have also been assigned DYT numbers and are discussed later in this article. The most common forms presenting early in life are DYT1, DYT5, and DYT11 dystonia, but DYT12, DYT23, and DYT26 may also present in childhood ( Table 7 -2). DYT1 early-onset primary generalized torsion dystonia is inherited in an autosomal dominant manner with incomplete penetrance (30% to 40%). 25 It is caused by mutations in TOR1A encoding torsinA, postulated to have a role in the regulation of subcellular compartments such as the nuclear envelope and endoplasmic reticulum. The vast majority of patients harbor the common GAG deletion. Symptom onset is usually in childhood or early adolescence, with dystonia usually beginning in one limb (Supplemental Digital Content 7-1, links.lww.com/ CONT/A185). In many patients, generalized dystonia usually ensues within 5 years of presentation (Supplemental Digital Content 7-2, links.lww.com/ CONT/A186).
DYT5 represents disorders of neurotransmission secondary to inherited dopa-responsive defects in the dopamine synthesis pathway. Guanosine triphosphate cyclohydrolase deficiency, also known as Segawa syndrome, is due to heterozygous mutations in GCH1, with incomplete penetrance. 26 Affected patients present from early childhood with limb dystonia, which can often mimic the symptoms and signs of diplegic cerebral palsy. Atypical
KEY POINT
h Primary genetic dystonias are defined as those generally associated with normal brain imaging. In childhood, reported forms include DYT1, DYT5, DYT11, DYT12, DYT23, and DYT6. 27 Associations of GCH1 carriers manifesting early-onset Parkinson disease have been reported. 28 DYT5b tyrosine hydroxylase deficiency represents another form of dopa-responsive dystonia but is more complex, often with concurrent features of parkinsonism, other motor features, and neurodevelopmental delay. 29 Although response to levodopa can lead to significant clinical benefit in type B (hypokinetic rigid phenotype), the earlier-onset type A subtype, associated with neonatal encephalopathy, is more drug resistant. Tyrosine hydroxylase deficiency is likely a phenotypic spectrum with a number of intermediate forms.
Patients with tyrosine hydroxylase deficiency often require much higher doses of levodopa to produce a therapeutic response than in autosomal dominant GCH1 deficiency. DYT11, or myoclonus dystonia syndrome, has clinical onset in childhood (median age 5 years) and frequently presents with early myoclonus affecting the upper limbs and neck with predominantly upper (but also lower) limb dystonia. 30 More pronounced truncal involvement is evident later in childhood and adolescence. Alcohol responsiveness is sometimes reported in older patients. Comorbid neuropsychiatric features are commonly reported. Affected patients have heterozygous mutations in SGCE, encoding the *-sarcoglycan protein.
Disease mechanisms are not yet fully elucidated, but mutations are postulated to impair targeting of *-sarcoglycan to the plasma membrane, affecting proteasomal degradation, protein glycosylation, and ectodomain shedding.
DYT12 is a rarer cause of genetic dystonia-parkinsonism due to autosomal dominant mutations in ATP1A3, encoding the "3 subunit of the Na + / K + Yadenosine triphosphatase (ATPase) pump. Affected patients usually present acutely or subacutely (from over a few minutes to months) with rostrocaudal progression of dystonia-parkinsonism and significant bulbar dysfunction. It has become clear that the clinical spectrum of ATP1A3-related disease is broad, encompassing a number of other overlapping phenotypes, including alternating hemiplegia of childhood as well as cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) syndrome. 31 The reasons for this phenotypic pleiotropy may be mutation dependent but are yet to be fully elucidated.
Heterozygous mutations of CACNA1B and KCTD17 have been described in extended families with childhoodonset myoclonus dystonia. 32, 33 Cardiac arrhythmias are additionally reported in those with CACNA1B variant p.R1389H. CaV2.2 channels carried less current when compared with wild-type channels; it is postulated that such altered channel properties could affect neurotransmitter release at excitatory and inhibitory channels. Screening of another patient cohort with myoclonus dystonia for this missense change has not identified further cases, with observation of this rare variant in control populations. The significance of this mutation remains yet to be fully determined. 34 KCTD17Yassociated protein is postulated to show significant putaminal expression, and KCTD17 gene mutations result in impairment of endoplasmic reticulumYdependent calcium signaling.
Genetic Chorea
A number of genes causing primarily choreiform dyskinesia have been reported. Often children with such conditions manifest chorea as part of a complex neurologic disorder, as exemplified by FOXG1 syndrome. 35 Benign hereditary chorea is a childhood-onset hyperkinetic movement disorder due to mutations in NKX2-1-AS1 (also known as NKX2-1 and TITF1). 36 Hypotonia is commonly described in infancy, with onset of chorea occurring from 2.5 to 3 years of age. Chorea is usually generalized and may be exacerbated by excitement or stress. Patients frequently manifest neonatal/infantile respiratory symptoms (including respiratory distress syndrome, obstructive small airways disease, and chronic interstitial lung disease) and thyroid abnormalities (congenital hypothyroidism). NKX2-1-AS1, from the natural killer (NK) gene family of highly conserved homeodomain-containing transcription factors, is postulated to have a role in embryonic development of the brain, lung, and thyroid gland. The combination of chorea with thyroid abnormalities is also described in Allan-Herndon-Dudley syndrome, an X-linked disorder associated with mutations in SLC16A2 encoding the monocarboxylate transporter 8 (MCT8). 37 Mutations lead to loss of function of this thyroid transporter, thereby impairing triiodothyronine transport capacity. Triiodothyronine has an important role in oligodendrocytes, inducing differentiation of the precursor as well as acting as a survival factor in these cells and influencing the distribution of myelin-related proteins. Individuals with Allan-Herndon-Dudley syndrome present with profound hypotonia and early limb spasticity. A complex movement disorder evolves over time, with prominent chorea and dystonia.
In 2014, mutations in MICU1 were identified in patients with cognitive impairment, proximal myopathy, and a progressive choreiform movement disorder. 38 MICU1 is a regulator of mitochondrial calcium uniporter (MCU), a Ca(2+)-selective ion channel located within the inner mitochondrial membrane Ca(2+) uniporter complex, and mutations disrupt mitochondrial Ca (2+) signaling.
Mutations in ADCY5 are the most recently recognized significant cause of progressive chorea in children.
Originally reported in patients presenting with familial dyskinesia with facial myokymia, 39 ADCY5-related disease comprises a wide clinical spectrum of disorders, including those that mimic dyskinetic cerebral palsy and conditions resembling TITF1 benign hereditary chorea (Case 7-2). 40 A relapsing-remitting disease course is often evident, and severe sleepdisrupting movements are frequently reported. Unlike TITF1 benign hereditary chorea, motor symptoms are typically progressive. Eliciting a history of sleep disturbance and disease progression can thus aid in clinical differentiation from benign hereditary chorea and cerebral palsy. ADCY5 is a membrane-bound adenylyl cyclase that generates adenosine 3 ¶,5 ¶cyclic monophosphate (cAMP) from an adenosine triphosphate (ATP). ADCY5 shows high expression in the brain striatum and in the nucleus accumbens, where it is responsible for 80% of adenylate cyclase activation. "-Adrenergic agonists stimulate ADCY5 through a G-proteinYcoupled receptor, which leads to a conformational change in the protein, facilitating formation of a catalytic pocket into which ATP binds. Pathogenic variants are predicted to lead to gain of function, increasing ADCY5 enzyme activity, either through "-adrenergic stimulation of the signal transduction pathway or by the interaction of the protein with other regulatory molecules.
KEY POINT
h The spectrum of genetic choreas is expanding and now includes disorders due to NKX2-1-AS1and ADCY5 mutations as well as those associated with more complex neurologic disorders such as FOXG1-related disease.
Genetic Paroxysmal Movement Disorders
A number of genetic movement disorders may present episodically ( Table 7 -3). Such paroxysmal dyskinesias typically present in childhood, often in children with normal neurodevelopment and behavior. Paroxysmal movements may be dystonic, choreiform, or ataxic and are often associated with specific triggers. 41 Detailed clinical history with direct questioning for precipitants of the movement disorder should be undertaken to aid in diagnosis. Many episodic movement disorders are caused by mutations in genes encoding channels; therefore, it is not surprising that such genes also account for other paroxysmal disor-ders such as epilepsy and migraine. Recognition of such syndromes is of significant clinical importance as many are amenable to treatment strategies ( Table 7 -3).
Genetic Myoclonus
Nonepileptic myoclonus is reported in a number of genetic conditions, often in association with other movement phenotypes. It is a prominent feature of myoclonus dystonia syndrome, as discussed earlier in this article, but is also reported in a number of inherited inborn errors of metabolism. 
Genetic Ataxia

Case 7-2
Following an unremarkable pregnancy, a male infant was born by emergency cesarean delivery for fetal bradycardia/decelerations. His parents were fit and healthy, with no significant family history of note. He was born in good condition, with excellent Apgar scores (9/10 at 1 and 5 minutes), and had an uneventful early neonatal course. Abnormal involuntary movements were noted from midinfancy, which were initially paroxysmal in nature, often occurring in clusters several times a day, with periods of relapse and remission. Choreiform limb movements were reported, with orolingual dyskinesia and mild truncal athetosis. The movement disorder progressed through early childhood, eventually becoming nonparoxysmal and continuous in nature. Involuntary movements began to disrupt his sleeping pattern. He did not show clinical response to a number of medications, including carbamazepine, levetiracetam, and tetrabenazine. Detailed neurologic investigation revealed normal brain and spine MRI, as well as normal blood, urine, and CSF screening for metabolic disorders. Routine diagnostic testing for NKX2-1-AS1, SLC2A1, and SGCE were negative. Whole exome sequencing undertaken on a research basis identified a previously reported mutation in ADCY5, which was confirmed to be de novo.
Comment. This case clearly exemplifies the typical disease pattern of ADCY5-related disease. Although dyskinetic cerebral palsy may be in the differential diagnosis here, a number of features in this child's history should prompt investigation of an alternative cause, including the relatively uneventful antenatal/postnatal course, evidence of normal neuroimaging, and clear disease progression with worsening of symptoms. Testing for benign hereditary chorea is reasonable, but negative sequencing for NKX2-1-AS1 should alert the clinician to look for other causes of benign hereditary chorea mimics and initiate ADCY5 testing. Further clinical clues toward this diagnosis include the disruption of sleep and progressive nature of disease. Table 7-4) , and many are complex progressive neurologic disorders. Friedreich ataxia is the most commonly reported, with clinical features of a progressive, mainly sensory, cerebellar ataxia with speech difficulties, absent reflexes, pyramidal tract signs with weakness, hypertrophic cardiomyopathy, diabetes mellitus, and sensorineural deafness. 42 Expanded guanine-adenine-adenine (GAA) repeats within intron 1 of frataxin (FXN) are thought to impair exon splicing with reduced protein expression. Frataxin is postulated to have a role in mitochondrial iron metabolism, and dyshomeostasis is thought to lead to increased free radical damage and oxidative stress. Ataxia with vitamin E deficiency can mimic many of the features seen in Friedreich ataxia and is characterized by a progressive ataxia with other cerebellar features of tremor, head titubation, and nystagmus, as well as myoclonus, dystonia, hyporeflexia, and retinitis pigmentosa. 43 Disease is caused by mutations in the "-tocopherol transfer protein, with impaired incorporation of vitamin E into very low density lipoproteins and subsequent excess loss of vitamin E. Low vitamin E levels are detectable on blood testing.
Ataxia telangiectasia presents with gait disturbance and truncal instability in early childhood, but choreiform movements and dystonia are also described. 44 Often, subtle abnormalities in ambulation precede the onset of ocular and cutaneous telangiectasia. Patients are at risk of immunodeficiency (secondary to low immunoglobulins) and lymphoreticular neoplasia. A raised "-fetoprotein can be a useful disease marker. The disease is due to Childhood to adulthood Ataxia, dystonia, and chorea also sometimes present, parkinsonism mutations in ATM, encoding a DNA repair protein. Clinically similar to ataxia telangiectasia are two forms of autosomal recessive ataxia with oculomotor apraxia due to mutations in APTX (ataxia with oculomotor apraxia type 1) and SETX (ataxia with oculomotor apraxia type 2). 45, 46 Both types present with a distinctive eye movement disorder in the context of ataxia, chorea, distal sensory axonal neuropathy, and progressive cerebellar atrophy on MRI. Ataxia of Charlevoix-Saguenay is a recently described condition originally in individuals originating from Quebec, Canada. Ataxia of Charlevoix-Saguenay is caused by mutations in SACS, with over 100 mutations reported to date in patients of different ethnicities. 47 Ataxia, dysarthria, spasticity, weakness, distal sensorimotor neuropathy, and nystagmus are commonly reported clinical symptoms. Distinctive neuroradiologic features include atrophy of the superior vermis and cerebellum with pontine linear hypointensities.
A number of both dominant and recessive spinocerebellar ataxia disorders may also present in childhood with prominent ataxia and gait instability, as well as other movement phenotypes (dystonia, chorea), speech disturbance, and progressive motor dysfunction ( Table 7 -4) . The increasing availability of targeted multiple gene panel testing for the ever-expanding list of spinocerebellar ataxia and other ataxia genes has improved the overall diagnostic rate for these childhoodonset ataxias, 48 although detection of certain mutations (eg, trinucleotide repeats, intronic variants) can still be challenging.
Genetic Parkinsonism
Rarely, genetic disorders that present predominantly with infantile or juvenile parkinsonism are reported. 2 Typi-cally, symptoms resemble those seen in idiopathic Parkinson disease, with bradykinesia, resting tremor, rigidity, and hypomimia. Pure parkinsonism is rarely reported, with most patients manifesting other movement disorders, most commonly dystonia (dystoniaparkinsonism) but also chorea and myoclonus. Cognitive impairment may also be a comorbid feature. A number of etiologies have been reported, including disorders of monoamine synthesis, metabolism, and transport as well as other inborn errors of metabolism (including mitochondrial disorders), disorders of brain metal ion accumulation, and juvenile-onset genetic parkinsonism due to mutations in the PARK genes ( Table 7 -3). Recognition of clinical features can be key to diagnosis, but adjunctive tests, such as CSF neurotransmitter analysis, CSF and blood lactate, muscle biopsy, dopamine transporter single-photon emission computed tomography (DAT-SPECT) nuclear imaging, and molecular genetic studies will often be needed to confirm the diagnosis.
Complex Inherited Neurometabolic Syndromes
Movement disorders are often a prominent clinical feature in a number of inborn errors of metabolism that present in childhood. Many of these conditions are complex, and patients often manifest a number of different movement phenotypes. Frequently, multisystem disease involvement exists, with cognitive and motor delay.
Dystonia, chorea, athetosis, ballismus, tremor, myoclonus, and parkinsonism are all described in disorders of monoamine synthesis and transport ( Continued on page 1175 Infancy
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, 49 Ataxia, chorea, and ballismus are also reported in a proportion of these patients.
Inherited mineral deposition disorders, including Wilson disease, neurodegeneration with brain iron accumulation, and SLC30A10 deficiency can all present with progressive neurologic phenotypes 50Y52 and prominent extrapyramidal features, including dystonia, chorea, tremor, parkinsonism, and spasticity. Characteristic MRI brain findings and molecular genetic testing can aid in the diagnosis of these disorders of metal ion accumulation ( Table 7 -5) .
A number of other inborn errors of metabolism can also present with movement disorders, including lysosomal disorders, mitochondrial diseases, amino acidopathies, organic acidurias, disorders of purine and creatine metabolism, and glucose transporter deficiency. Detailed metabolic screening is therefore often warranted in patients with complex progressive neurologic syndromes associated with motor phenotypes (Case 7-3) ( Table 7 -5) .
A number of genes have also been identified in infantile and childhood-onset bilateral striatal necrosis ( Table 7 -5) .
Mitochondriocytopathies are frequently associated with bilateral striatal necrosis. ADAR1 has emerged as an impor-tant cause, accounting for a significant proportion of patients with bilateral striatal necrosis who present with severe progressive medically intractable generalized dystonia. 53 An interferon signature, measuring upregulation of interferon-stimulated genes, can aid in the diagnosis of this bilateral striatal necrosis subtype. The finding of bilateral striatal necrosis should prompt investigation for treatable causes, including thiamine transporter deficiency due to mutations in SLC19A3, where initiation of biotin and thiamine supplementation can lead to marked improvement or even reversal of clinical symptoms in tandem with radiologic improvement of the striatal features. 54 Structural abnormalities of the basal ganglia may also be seen in some genetic hypomyelinating disorders. In 2013, TUBB4A was identified as the genetic cause of hypomyelination with atrophy of the basal ganglia and cerebellum. 55 Mutations are postulated to disrupt tubulin dimerization, microtubule polymerization, or microtubule stability. Extrapyramidal features, namely dystonia, rigidity, and, rarely, choreoathetosis, are reported in affected patients. A number of patients also manifest ataxia and gait instability. TUBB4A-related diseases encompass a broad spectrum, from hypomyelination with atrophy of the basal ganglia and cerebellum to other hypomyelinating disorders and also whispering dysphonia ( Table 7 -5). The reasons for this phenotypic pleiotropy remain to be fully elucidated. 56 
Treatment Strategies for Genetic Childhood Movement Disorders
Treatment strategies for children with genetic movement disorders are usually dictated by disease etiology and movement disorder phenomenology. Children with dystonia of undetermined cause will often have an early trial of levodopa to rule out a treatable dopa-responsive dystonia. 27 Symptomatic treatment of dystonia is managed with a number of different agents, including baclofen, trihexyphenidyl, the benzodiazepines, 57 and, more recently, clonidine and gabapentin. More invasive therapies, such as intrathecal baclofen and DBS, are also used. DBS is particularly effective for children with primary dystonia due to DYT1 58 but has also been used as palliation in a number of other genetic disorders, such as pantothenate kinaseYassociated neurodegeneration. Chorea can often be difficult to manage from a therapeutic perspective, but tetrabenazine, benzodiazepines, and antiepileptic drugs (eg, levetiracetam, sodium valproate, carbamazepine) can be used. 59 The paroxysmal disorders have specific treatments,
Case 7-3
A female infant was born to fit and healthy consanguineous parents. She was born in good condition and did not require any resuscitation, nor was she admitted to the neonatal intensive care unit. She was discharged on day 2 of life. From the early neonatal period, she was irritable, with difficulty in feeding and a disrupted sleep pattern. The parents reported that often she would look as if she were half asleep, with her eyes half closed. She was profoundly hypotonic and had delay in her motor milestones. By 2 to 3 months of age, abnormal eye movements were noted, and the family described periods when her eyes would deviate to the right and fixate in an upward gaze lasting from seconds to several hours. Often during these periods her body would be arched and hands fisted. The parents also noted that she always seems to have a cold with nasal congestion, and even during the winter, her hands and the back of her head were sweaty. During infancy, she developed a complex movement disorder, with dystonic posturing of her limbs, truncal athetosis, tremulous hand movements, and occasional myoclonic jerks. A diagnostic lumbar puncture was undertaken, and CSF neurotransmitter analysis revealed a low homovanillic acid, low 5-hydroxyindoleacetic acid, and normal pterin profile. CSF 3-O-methyldopa and 5-hydroxytryptophan were markedly elevated. Further testing revealed low aromatic L-amino acid decarboxylase plasma enzyme activity. Molecular testing revealed that she was a compound heterozygote for two mutations in the DDC gene, one reported in association with aromatic L-amino acid decarboxylase deficiency and the other a novel 2-base pair deletion.
Comment. This case illustrates a child with a very-early-onset neurologic disorder, characterized by severe motor delay, hypotonia, and mixed movement symptomatology. The ptosis and severe hypotonia could indeed be presenting features of neuromuscular disease, although the complex movement disorder and presence of autonomic features (sweating, nasal congestion, ptosis) should prompt CSF neurotransmitter analysis to look for disorders of monoamine metabolism. This patient's CSF findings are indeed classic for aromatic L-amino acid decarboxylase deficiency, later confirmed by enzyme assay and molecular genetic testing. This patient's first mutation has already been reported in the literature associated with aromatic L-amino acid decarboxylase deficiency. The second mutation, although novel as a 2-base pair deletion, will lead to a frameshift with significant alteration to the protein and likely premature stop. which can often be very effective ( Table 7- 4) . Genetic parkinsonian disorders are treated with either levodopa therapy or dopaminergic drugs such as pramipexole, ropinirole, and rotigotine. Neurotransmitter disorders and other complex neurometabolic syndromes require specific disease-targeted treatments, often necessitating consultation with a specialist in the field. All children with complex genetic syndromes should be under the care of a multidisciplinary team, including a neurologist with expertise in movement disorders with close links to physical, occupational, and speech and language therapists. Regular input from a general pediatrician to monitor general health issues, vision, and hearing and for orthopedic and secondary gastrointestinal complications is also an integral part of routine care. Genetic counseling to discuss the disease risk in future pregnancies should also be offered to affected families.
PSYCHOGENIC MOVEMENT DISORDERS IN CHILDREN
Psychogenic presentations represent a significant proportion of acute presentations to neurology services and are important as they often represent a significant and complex issue for the child. Early recognition and treatment are considered important to provide the best chance of a good outcome. The issue of whether these problems should be termed psychogenic or functional is under debate but not discussed in this article, and little doubt exists that our understanding of these disorders is changing. Careful clinical history and observation is essential. Sometimes the diagnosis is straightforward; however, sometimes prolonged observation is needed for diagnosis of difficult cases. Psychogenic movement disorders occur more commonly in adolescents and in females, and a diagnosis in a young child under 10 years of age should be made with caution (although they do occur). The hallmarks of psychogenic movement disorders are an acute, often explosive, onset with a short time to maximum severity (often hours or days), incongruous characteristic (atypical or odd) inconsistent findings, and inconsistent performance relative to the severity of movements (eg, the patient is able to use a mobile phone despite violent movements). Pseudomyoclonus or pseudotremor are the most common psychogenic movement disorder movements. Pseudodystonia, akinesia, and chorea are uncommon, although occasionally observed. 23 The classic patient may have a history of high performance in academics or sporting activities, a predisposition to anxiety, some preceding psychosocial stressors, and, sometimes, an acute, often minor, stress (eg, dental procedure or infection).
It is essential to approach the problem with care and empathy and to perform necessary investigations to reassure the patient and family that no serious brain pathology, such as a tumor, exists. Neuroimaging is almost always necessary to exclude a structural or metabolic cause for symptoms. Explanation of the problem is important to the child and family, and this may require repeated consultations and discussions before the child and family accept the likely explanation (Case 7-4). Arguably the most useful test can be a second opinion from an experienced colleague. 60 
CONCLUSION
Scientific advances have certainly improved diagnosis and available treatments for children with movement disorders. Careful clinical history, detailed examination, and review of KEY POINTS h Genetic movement disorders are increasingly being recognized and diagnosed in children. Often, chromosomal microarray is an early investigation in such children to identify copy number variants accounting for disease phenotypes. Further genetic testing is guided by clinical history, features on examination, and radiologic or metabolic biomarkers. The evolution of multiple gene panels and whole exome sequencing technologies has further improved diagnostic approaches for this group of patients.
h Early recognition and intervention as well as involving a multidisciplinary team to rehabilitate the patient both physically and psychologically are essential in management of psychogenic movement disorders. Treating psychogenic movement disorders can be rewarding to the child, family, and health practitioners. video recordings can aid diagnosis and help direct further diagnostic strategies. Genetic advances will allow elucidation of new disease pathways that may inform future targeted therapeutic strategies. DBS and novel treatment approaches such as gene therapy may also play an increasing role in the future for pharmacoresistant and neurodegenerative childhood movement disorders.
VIDEO LEGENDS Supplemental Digital
Content 7-1 DYT1 dystonia. Video shows a 10-year-old girl with genetically confirmed DYT1 dystonia who presents with progressive limb dystonia, predominantly affecting the right arm.
links.lww.com/CONT/A185
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Supplemental Digital Content 7-2
Complete resolution of DYT1 dystonia with trihexyphenidyl. Video shows the same patient as in Supplemental Digital Content 7-1 6 years later. She is now 16 years old and has complete control of her dystonia with trihexyphenidyl 6 mg 3 times per day as monotherapy.
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Supplemental Digital Content 7-3
Aromatic L-amino acid decarboxylase deficiency. Video shows a 2.5-year-old girl with aromatic L-amino acid decarboxylase deficiency. While sitting during examination, the patient has an oculogyric crisis with deviation of the eyes to the right and upward. Her right Case 7-4 A 12-year-old girl with no significant medical problems presented with shaking movements of the arms. She had attended school as usual the day before but had onset of shaking movements the preceding evening, and her condition had deteriorated dramatically over the course of the next day. She had no other change in function. Examination revealed dramatic coarse shaking of the upper limbs but no abnormal movements of the legs, head, or trunk. Her walking revealed unsteadiness with significant wobbling but without falls. During observation, it was noted that her symptoms fluctuated significantly; she was observed to use her mobile phone normally without shaking, and her shaking varied according to the people around her. Her behavior, thinking, and memory were normal, and formal neurologic examination was also unrevealing. On subsequent history, it became apparent that she had been the victim of significant bullying at school. The school described her as a kind, diligent, and sensitive girl who was training 5 nights a week in state-level athletic competition. MRI brain and EEG were normal.
Comment. The incongruous and inconsistent nature of this patient's movement disorder led to a diagnosis of a psychogenic movement disorder, presumably secondary to the significant stressors. Psychological input uncovered some baseline anxiety and fears of failure with perfectionism and some obsessive-compulsive behavior. A confident diagnosis and acceptance of the diagnosis by the family, followed by a multidisciplinary rehabilitation with physical therapy and psychological input resulted in a rapid improvement and return to normal function. arm is held extended and pronated in a dystonic posture. Examination reveals four-limb hypotonia, bilateral ptosis, mild mouth tenting, severe axial hypotonia, an overall paucity of spontaneous movement and left foot clawing.
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